The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Granules now has a total of 67 ANDA approvals from the USFDA
VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease
Subscribe To Our Newsletter & Stay Updated
